Neuprozyme Therapeutics ApS: Financial statements 2018
CVR: 40010106
Source: annual report 2018, Danish Business Authority
01/07/2017 – 30/06/2018
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2018. In 2018, the company reported a net result of DKK 0. Equity in the 2018 report amounted to DKK 50,000. The solvency ratio was 100%.
- Profit/Loss
- DKK 0
- Equity
- DKK 50,000
- Total Assets
- DKK 50,000
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of September 19, 2018, ALBJERG STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Neuprozyme Therapeutics ApS.
As of September 19, 2018, Lone Ballegaard Pedersen has joined the board of directors of Neuprozyme Therapeutics ApS.
As of September 19, 2018, John Pedersen has joined the board of directors of Neuprozyme Therapeutics ApS.
As of September 19, 2018, John Pedersen is registered as director of Neuprozyme Therapeutics ApS.
As of September 19, 2018, LJP HOLDING ApS is registered as an owner of Neuprozyme Therapeutics ApS with an ownership share of 100%.
Neuprozyme Therapeutics ApS was founded on September 19, 2018.
About Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.